A significant financial infusion is set to propel deupirfenidone, an investigational therapy for idiopathic pulmonary fibrosis (IPF), into its crucial Phase III clinical trial, potentially reshaping the treatment landscape for this devastating lung disease.
London, UK – July 3, 2026 – Celea Therapeutics has announced the successful closure of a $180 million financing round, a substantial capital injection earmarked to fuel the upcoming pivotal Phase III SURPASS-IPF clinical trial of its lead drug candidate, deupirfenidone (LYT-100). This development marks a critical milestone for the company and offers renewed hope for patients battling idiopathic pulmonary fibrosis (IPF), a rare, progressive, and ultimately fatal lung disease characterized by irreversible scarring and declining lung function.
The substantial funding was secured from a distinguished group of investors, including prominent names such as RA Capital Management, PureTech Health, Leaps by Bayer, a major US healthcare fund, and a sovereign wealth fund. Their collective commitment underscores a strong belief in the therapeutic potential of deupirfenidone and Celea Therapeutics’ strategic vision.
The planned Phase III SURPASS-IPF trial, a randomized, global, double-blind, and head-to-head study, is slated to commence in early Q3 2026. This pivotal trial will directly compare deupirfenidone, administered at a dosage of 825mg three times daily (TID), against pirfenidone, the current standard of care, dosed at 801mg TID. The study will enroll adult patients diagnosed with IPF who are not currently receiving any background therapy, aiming to rigorously assess the efficacy and safety of deupirfenidone as a potential new benchmark for IPF treatment.
The Promise of Deupirfenidone: A Next-Generation Antifibrotic
Deupirfenidone represents an investigational, next-generation antifibrotic agent. Its development is rooted in the established efficacy of pirfenidone, a molecule already approved for the treatment of IPF. However, deupirfenidone is a deuterated form of pirfenidone. This structural modification aims to enhance the drug’s pharmacokinetic profile, potentially leading to improved tolerability and sustained therapeutic levels. The company posits that deupirfenidone has the potential to establish a new standard of care for individuals living with IPF, offering a more effective and potentially better-tolerated treatment option.
"People living with IPF continue to face a devastating disease with limited treatment options, and we believe deupirfenidone has the potential to deliver meaningful improvements for patients," stated Sven Dethlefs, CEO of Celea Therapeutics. "We are grateful for the support and confidence of this exceptional group of investors, whose commitment enables us to initiate the Phase III SURPASS-IPF trial and advance development of deupirfenidone with the speed and focus this community deserves."
The significance of this financing extends beyond simply enabling the commencement of the Phase III trial. It provides Celea Therapeutics with the necessary resources to conduct a comprehensive, large-scale global study, gather robust data, and navigate the complex regulatory pathways required for drug approval. The company’s proactive engagement with regulatory bodies, as evidenced by its meeting with regulators in September 2025 regarding the potential launch of this Phase III trial, further demonstrates a strategic and well-prepared approach to advancing deupirfenidone.
A Detailed Look at the SURPASS-IPF Trial Design
The upcoming SURPASS-IPF trial is meticulously designed to provide definitive evidence of deupirfenidone’s efficacy. The primary efficacy endpoint will be the change from baseline in absolute forced vital capacity (FVC) at week 52. FVC is a critical measure of lung function, reflecting the total amount of air a person can forcibly exhale after taking their deepest possible breath. A slower decline in FVC is a key indicator of treatment success in IPF.
The head-to-head comparison against pirfenidone is particularly noteworthy. This design allows for a direct assessment of whether deupirfenidone offers advantages over the current established therapy, whether in terms of efficacy, safety, or patient tolerability. The decision to administer deupirfenidone at 825mg TID is based on data from earlier trials, suggesting an optimal balance of therapeutic benefit and acceptable side effect profile.
The randomized, double-blind nature of the trial is crucial for minimizing bias. In a double-blind study, neither the participants nor the researchers know which treatment is being administered, preventing preconceived notions from influencing the results. The global scope of the trial ensures that the data collected will be representative of diverse patient populations and geographical regions, strengthening the generalizability of the findings.
Supporting Data: From Phase IIb to Phase III Aspirations
Celea Therapeutics’ confidence in deupirfenidone is underpinned by promising data from previous clinical studies. The global Phase IIb ELEVATE IPF trial provided early indications that deupirfenidone may effectively stabilize lung function decline over a period of at least 26 weeks when used as a monotherapy. Furthermore, initial data from the open-label extension (OLE) of this study suggested that these beneficial effects were sustained through at least 52 weeks.
These positive outcomes from the Phase IIb trial were instrumental in informing the design of the SURPASS-IPF study and in demonstrating to regulators and investors the drug’s potential. The orphan drug designation granted to deupirfenidone by both the European Commission and the U.S. Food and Drug Administration (FDA) further signifies the unmet medical need for IPF treatments and the potential of deupirfenidone to address this need. Orphan drug status often comes with incentives, such as market exclusivity and fee waivers, which can accelerate the development and commercialization process.
Beyond IPF, Celea Therapeutics also envisions deupirfenidone as a potential treatment option for other fibrotic conditions, including progressive fibrosing interstitial lung diseases. This broader therapeutic potential could significantly expand the market for the drug and its impact on patients with a range of debilitating fibrotic disorders.
Understanding Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive, and ultimately fatal lung disease that affects an estimated 100,000 people in the United States and a similar number in Europe. The term "idiopathic" signifies that the cause of the disease is unknown. It is characterized by a gradual and irreversible thickening and scarring of lung tissue, known as fibrosis. This scarring stiffens the lungs, making it increasingly difficult to breathe and leading to a progressive decline in lung function.
Symptoms of IPF typically include shortness of breath, a dry cough, fatigue, and unintentional weight loss. As the disease progresses, patients may require supplemental oxygen and eventually may need a lung transplant. Currently, there are only two FDA-approved medications for IPF: pirfenidone and nintedanib. While these treatments can slow the rate of lung function decline, they do not cure the disease and have varying degrees of efficacy and side effect profiles. The limited treatment options underscore the urgent need for new and improved therapies.
The irreversible nature of lung scarring in IPF means that once damage has occurred, it cannot be repaired. Therefore, the focus of treatment is primarily on slowing the progression of the disease and managing symptoms. The development of antifibrotic agents like deupirfenidone represents a significant advancement in this regard, aiming to halt or significantly slow down the fibrotic process.
Investor Confidence and the Future of IPF Treatment
The substantial investment from a consortium of high-caliber investors, including RA Capital Management, PureTech Health, and Leaps by Bayer, signals a strong vote of confidence in Celea Therapeutics and the therapeutic promise of deupirfenidone. These investors are known for their discerning approach to identifying and supporting promising biotechnology companies with innovative drug candidates.
RA Capital Management is a prominent investment firm with a focus on healthcare, known for its deep understanding of the pharmaceutical and biotechnology sectors. PureTech Health is a biotherapeutics company focused on creating and growing innovative healthcare businesses, often leveraging novel scientific platforms. Leaps by Bayer, the impact investment arm of Bayer, is dedicated to investing in transformative science and technology that can address some of the world’s most pressing health and agricultural challenges. The participation of a major US healthcare fund and a sovereign wealth fund further attests to the perceived de-risking of deupirfenidone’s development pathway and its potential for significant market impact.
This substantial financial backing not only facilitates the critical Phase III trial but also positions Celea Therapeutics for future development milestones, including potential commercialization efforts. The early involvement of such reputable investors suggests that deupirfenidone has successfully navigated early-stage development and demonstrated sufficient scientific and clinical merit to warrant significant financial commitment.
The successful completion of the SURPASS-IPF trial could have profound implications for the management of IPF. If deupirfenidone proves to be superior to or more tolerable than existing therapies, it could become the new gold standard of care, significantly improving the quality of life and potentially extending the survival of patients diagnosed with this debilitating disease. Furthermore, the potential application of deupirfenidone to other fibrotic lung diseases could broaden its impact and solidify Celea Therapeutics’ position as a leader in the field of antifibrotic therapies.
As the pharmaceutical industry continues its relentless pursuit of innovative treatments for rare and life-threatening conditions, the advancement of deupirfenidone into its pivotal Phase III trial represents a beacon of hope. The coming years will be critical as Celea Therapeutics embarks on this crucial stage of development, with the eyes of the medical community and patient advocacy groups firmly fixed on the potential of this promising investigational therapy.
About the Author
